Hepatitis C News and Research RSS Feed - Hepatitis C News and Research

Hepatitis C is a blood-borne virus that infects the liver, where it causes significant inflammation, damage and disruption of normal liver function. According to estimates by the World Health Organization, around 3 to 4 million people worldwide are infected with hepatitis C every year.

The hepatitis C virus is usually transmitted through contact with the blood of an infected individual and, most commonly, people catch it through sharing contaminated needles when injecting illegal drugs.

Hepatitis C infection is categorized into an acute and a chronic stage. The acute phase describes the first 6 months of infection when there are not necessarily any symptoms. Around one quarter of people manage to clear the infection during this stage before disease progresses to the chronic stage.

People who go on to develop chronic hepatitis C may develop jaundice which turns the skin and whites of the eyes yellow. This is caused by the build-up of a yellow-colored substance in the blood called bilirubin that would usually be broken down by the liver if it was healthy. Chronic infection may eventually cause fibrosis and scarring (cirrhosis) of the liver, liver cancer or end stage liver failure.

Hepatitis C can be treated with antiviral medications that that are designed to disrupt the multiplication of virus particles inside the body and prevent liver damage.

New research provides new hope for liver transplant patients with recurring hepatitis C

New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV). [More]
EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

New ways to differentiate between chronic and self-clearing infections may help towards effective patient management and reduce drug costs. But there are major challenges in implementation. [More]

Viral hepatitis linked to more deaths than HIV across EU countries

Mortality from viral hepatitis is significantly higher than from HIV/AIDS across EU countries, according to results from The Global Burden of Disease Study 2010 (GBD 2010) which was announced for the first time today at the International Liver CongressTM 2014. [More]
Clinical Research Forum announces winners of third annual Top 10 Clinical Research Achievement Awards

Clinical Research Forum announces winners of third annual Top 10 Clinical Research Achievement Awards

The Clinical Research Forum has announced the winners of its third annual Top 10 Clinical Research Achievement Awards. The winning projects represent the outstanding examples of research projects that benefit the health and well-being of the general public. [More]
Johns Hopkins student receives 2014 Excellence in Public Health Award

Johns Hopkins student receives 2014 Excellence in Public Health Award

Ramy El-Diwany, a fifth-year M.D./Ph.D. student at the Johns Hopkins University School of Medicine, has won a 2014 Excellence in Public Health Award from the U.S. Public Health Service (USPHS) Physician Professional Advisory Committee for his contributions to community health services. [More]

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection. [More]
Portrait of newly insured takes shape

Portrait of newly insured takes shape

Early enrollees in the health law's marketplaces were more likely to use expensive specialty drugs and less likely to use contraceptives, according to an analysis of two months of drug claims data by Express Scripts. A Rand analysis, meanwhile, argues that most of the newly insured signed up with an employer rather than buying it through the marketplaces. [More]
First Edition: April 9, 2014

First Edition: April 9, 2014

Today's headlines include coverage of the release of Medicare billing and utilization data, as well as early insights into who enrolled in health coverage as a result of the health law. [More]

EASL to present online HCV management recommendations at the ILCTM

The European Association for the Study of the Liver (EASL) will this week be announcing new on-line recommendations on the management of hepatitis C (HCV) at the International Liver Congress- (ILC). [More]
Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have submitted new drug applications (NDAs) with the U.S. Food and Drug Administration (FDA) for the investigational products daclatasvir (DCV), an NS5A replication complex inhibitor, and asunaprevir (ASV), a NS3 protease inhibitor. [More]
Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis. [More]

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Gilead Sciences, Inc. today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection. [More]
ABL enters into licensing agreement with CRP-Santé for COMET software

ABL enters into licensing agreement with CRP-Santé for COMET software

Advanced Biological Laboratories (ABL) S.A., a Luxembourg-based company today announced that it has entered into an exclusive worldwide licensing agreement with CRP-Santé, a Luxembourg-based public research center active in the field of clinically oriented biomedical research, for its COMET (COntext-based Modeling for Expeditious Typing) software, a tool designed to rapidly analyze and optimally subtype large genetic data sets arising from epidemiological or antiretroviral resistance in the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) fields. [More]

Expensive hepatitis drug draws huge sales

The demand for Gilead Sciences' Sovaldi, which costs $1,000 a pill, indicates how hard it is for insurers to curb the use of life-saving medicines. Meanwhile Humana names a former Goldman Sachs executive as finance chief. [More]
First Edition: April 1, 2014

First Edition: April 1, 2014

Today's early morning highlights from the major news organizations, including an array of stories as the health law's enrollment period comes to a close [More]

Viewpoints: Nothing 'magical' about 6 million enrollees; the high cost of hep C medicine

Big news this afternoon on the Affordable Care Act: The ACA exchange signups have reached the 6 million mark. With a few more days to go before the open sign-up period closes (well, sort of) it looks like the original 7 million estimate -- which the Congressional Budget Office had revised downward after the botched October roll-out of the federal exchange -- is going to be pretty close to the mark. [More]

Johns Hopkins researchers use 3-D MRI scans to accurately measure tumor viability and death

In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized 3-D MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy - delivered directly through a tumor's blood supply - is working. [More]
HIV and Hepatitis C vaccines now closer to reality

HIV and Hepatitis C vaccines now closer to reality

Plans for a new type of DNA vaccine to protect against the deadly HIV and Hepatitis C viruses have taken an important step forward, with University of Adelaide researchers applying for a patent based on groundbreaking new research. [More]

Democratic lawmakers ask hepatitis C drugmaker to justify price

A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21). [More]
Transgene raises €65.5M via two-step capital increase

Transgene raises €65.5M via two-step capital increase

Transgene SA, a French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases, announces that it has raised a total of €65.5 million via a two-step capital increase. [More]